Table 2 16 IHC markers and PFS in the biomarker population.

From: Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer

  

PFS (months)

P value (HR, 95% CI)

Pinteraction

Sunitinib

Sorafenib

Sunitinib

Sorafenib

HIF-1α

High

11

13

0.239 (1.496, 0.765–2.928)

0.994 (1.002, 0.521–1.930)

0.847

Low

18.9

14.4

HIF-2α

High

25.35

12.6

0.027 (0.462, 0.234–0.915)

0.107 (1.729, 0.888–3.365)

<0.001

Low

8

25

CAIX

High

27

17.7

0.027 (0.473, 0.244–0.917)

0.400 (1.340, 0.678–2.651)

0.095

Low

9.05

12

VEGF

Low

13.4

10

0.218 (0.659, 0.340–1.280)

0.027 (0.423, 0.197–0.909)

0.347

High

14.9

undefined

VEGFR1

High

13.4

41

0.508 (1.253, 0.647–2.430)

0.032 (0.463, 0.229–0.934)

0.038

Low

16.15

10.1

VEGFR2

High

15.6

13.4

0.908 (0.958, 0.465–1.976)

0.638 (1.197, 0.567–2.528)

0.187

Low

11

13.3

VEGFR3

High

11

9.75

0.303 (1.434, 0.722–2.845)

0.325 (1.391, 0.721–2.683)

0.263

Low

18.9

21.1

PDGFB

High

17

15

0.599 (0.776, 0.259–1.930)

0.384 (1.393, 0.660–2.939)

0.087

Low

11

29.5

PDGFRB

High

12.2

63.5

0.345 (1.373, 0.711–2.651)

0.032 (0.479, 0.245–0.937)

0.017

Low

15.6

10

CD31

High

23.4

13

0.019 (0.429, 0.212–0.869)

0.994 (1.002, 0.521–1.930)

0.010

Low

7.25

14.4

CD44

High

10.9

11

0.026 (2.259, 1.101–4.637)

0.067 (1.949, 0.955–3.975)

0.838

Low

41.5

25

bcl-xL

High

6.8

14.4

0.001 (3.530, 1.739–7.168)

0.868 (1.057, 0.551–2.028)

0.084

Low

44.5

12.35

KIT

High

13.4

9.4

0.8678 (0.867, 0.478–1.546)

0.198 (1.558, 0.793–3.063)

0.622

Low

16.7

18

p21

High

11

9.3

0.039 (2.120, 1.037–4.333)

0.135 (1.674, 0.851–3.291)

0.411

Low

45.3

41

RET

High

12.05

9.5

0.377 (1.389, 0.670–2.876)

0.065 (2.051, 0.955–4.405)

0.090

Low

16.7

undefined

FLT-3

High

14.25

14.85

0.747 (0.895, 0.456–1.756)

0.921 (1.034, 0.538–1.986)

0.422

Low

14.5

13.4

  1. Survival data are median, p values and HRs for sunitinib- and sorafenib-treated groups are both come from multivariable analysis, they compare higher biomarker group to lower biomarker group; pinteraction values are come from multivariate analysis (Cox model analysis) to assess the potential differential effects of immunostainings between the two treatment groups.
Back to article page